Edition:
India

TherapeuticsMD Inc (TXMD.OQ)

TXMD.OQ on NASDAQ Stock Exchange Global Select Market

5.59USD
9:57pm IST
Change (% chg)

$0.08 (+1.45%)
Prev Close
$5.51
Open
$5.52
Day's High
$5.63
Day's Low
$5.52
Volume
217,177
Avg. Vol
512,198
52-wk High
$7.00
52-wk Low
$3.50

Chart for

About

TherapeuticsMD, Inc. is a women's healthcare company engaged in creating and commercializing products for women. The Company is focused on pursuing regulatory approvals and pre-commercialization activities necessary for commercialization of its hormone therapy pharmaceutical products. Its drug candidates used in clinical trials... (more)

Overall

Beta: 0.95
Market Cap(Mil.): $1,082.14
Shares Outstanding(Mil.): 216.43
Dividend: --
Yield (%): --

Financials

  TXMD.OQ Industry Sector
P/E (TTM): -- 30.95 32.74
EPS (TTM): -0.45 -- --
ROI: -68.00 14.84 14.38
ROE: -68.00 16.34 16.07

BRIEF-TherapeuticsMD Enters Into Negotiations With U.S. FDA For TX-004HR

* ENTERED INTO NEGOTIATIONS WITH U.S. FOOD AND DRUG ADMINISTRATION REGARDING PROPOSED LABEL FOR TX-004HR

11 Apr 2018

BRIEF-TherapeuticsMD Announces FDA Acceptance Of New Drug Application For Tx-001Hr

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION (NDA) AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-001HR

09 Mar 2018

BRIEF-TherapeuticsMD Q4 Loss Per Share $0.10

* THERAPEUTICSMD ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS

21 Feb 2018

BRIEF-TherapeuticsMD Submits New Drug Application For TX-001HR

* THERAPEUTICSMD ANNOUNCES SUBMISSION OF NEW DRUG APPLICATION FOR TX-001HR

29 Dec 2017

BRIEF-Therapeuticsmd Announces FDA Acceptance Of New Drug Application And PDUFA Date For TX-004HR

* THERAPEUTICSMD ANNOUNCES FDA ACCEPTANCE OF NEW DRUG APPLICATION AND PRESCRIPTION DRUG USER FEE ACT (PDUFA) DATE FOR TX-004HR

20 Dec 2017

BRIEF-TherapeuticsMD reports Q3 loss per share of $0.07

* TherapeuticsMD announces third quarter 2017 financial results

06 Nov 2017

BRIEF-TherapeuticsMD announces plan to resubmit the new drug application for TX-004HR

* TherapeuticsMD Inc announces plan to resubmit the new drug application for TX-004HR

06 Nov 2017

Earnings vs. Estimates